Background: High fibroblast growth factor-23 (FGF-23) levels are associated with adverse outcomes. We studied the responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD) and healthy control patients.
Methods: Thirty patients were enrolled: 18 normophosphatemic CKD subjects and 12 healthy controls.